Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference

Canadian Journal of Cardiology

Volumn 27, Issue 5, 2011, Pages 635-662

  Mancini, G B John ^a   Baker, Steven ^b   Bergeron, Jean ^c   Fitchett, David ^d   Frohlich, Jiri ^a   Genest, Jacques ^e   Gupta, Milan ^b   Hegele, Robert A ^f   Ng, Dominic ^d   Pope, Janet ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANACETRAPIB; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; COLESEVELAM; DALCETRAPIB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; METHOTREXATE; MEVALONIC ACID; MEVINOLIN; MIPOMERSEN; NEUROLEPTIC AGENT; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; PREDNISONE; ROSUVASTATIN; SATURATED FATTY ACID; SIMVASTATIN; TORCETRAPIB; UNINDEXED DRUG; VITAMIN D;

ABDOMINAL DISCOMFORT; ACANTHOSIS NIGRICANS; ACID MALTASE DEFICIENCY; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ALDOSTERONE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; ARTHRALGIA; ARTHRITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROTHROMBOSIS; AUTOIMMUNE HEPATITIS; BLOOD PRESSURE; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARNITINE PALMITOYL TRANSFERASE II DEFICIENCY; CHOLELITHIASIS; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONFUSION; COUNSELING; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DERMATOMYOSITIS; DIABETES MELLITUS; DIET; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME DEFICIENCY; ERECTILE DYSFUNCTION; FAT INTAKE; FATIGUE; FLUSHING; FULMINANT HEPATIC FAILURE; GALLBLADDER DISEASE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLYCOGEN STORAGE DISEASE TYPE 5; GRAPEFRUIT JUICE; HALLUCINATION; HEALTH BEHAVIOR; HEALTH CARE; HEALTH CARE FACILITY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEMATURIA; HEPATOBILIARY DISEASE; HIP OSTEOARTHRITIS; HOSTILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOTHYROIDISM; INJECTION SITE REACTION; INSOMNIA; INTERSTITIAL LUNG DISEASE; KENNEDY DISEASE; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIPOPHILICITY; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT HYPERTHERMIA; MEDICAL SPECIALIST; METABOLIC DISORDER; MITOCHONDRIAL MYOPATHY; MORTALITY; MUSCLE CRAMP; MUSCLE PHOSPHORYLASE B KINASE DEFICIENCY; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; MYOADENYLATE DEAMINASE DEFICIENCY; MYOPATHY; MYOSITIS; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; POLYMYOSITIS; POMEGRANATE JUICE; PROTEINURIA; RASH; RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; RHEUMATIC POLYMYALGIA; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; TENDINITIS; TERTIARY HEALTH CARE; THROMBOSIS; TREATMENT OUTCOME; URINARY EXCRETION; WEIGHT REDUCTION;

CANADA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 81255165866     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.05.007     Document Type: Review

References (239)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Mora S., Glynn R.J., Hsia J., et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia. Results from the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121:1069-1077.
3. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
4. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356:2388-2398.
5. Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C.
6. Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858-868.
7. Thompson P.D., Clarkson P.M., Rosenson R.S. An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C-76C.
8. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581-585.
9. Giordano N., Senesi M., Mattii G., et al. Polymyositis associated with simvastatin. Lancet 1997, 349:1600-1601.
10. Hansen K.E., Hildebrand J.P., Ferguson E.E., et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671-2676.
11. Hill M.D., Bilbao J.M. Case of the month: February 1999--54 year old man with severe muscle weakness. Brain Pathol 1999, 9:607-608.
12. Mascitelli L., Pezzetta F., Goldstein M.R. Detrimental effect of statin therapy in women with fibromyalgia. Arch Intern Med 2008, 168:1228-1229.
13. Goeb V., Guillemant N., Vittecoq O., Le Loet X. Cerivastatin-induced polymyalgia rheumatica-like illness. Clin Rheumatol 2004, 23:179.
14. Liebhaber M.I., Wright R.S., Gelberg H.J., et al. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999, 115:886-889.
15. Sauret J.M., Marinides G. Rhabdomyolysis. Am Fam Physician 2002, 65:907-912.
16. Baker S.K. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005, 31:572-580.
17. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008, 359:789-799.
18. Tirona R.G., Leake B.F., Merino G., et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001, 276:35669-35675.
19. Vladutiu G.D., Simmons Z., Isackson P.J., et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006, 34:153-162.
20. Jacobson T.A. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009, 5:507-518.
21. Knauer M.J., Urquhart B.L., Meyer zu Schwabedissen H.E., et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010, 106:297-306.
22. Berthold H.K., Naini A., Di Mauro S., et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006, 29:703-712.
23. Chariot P., Abadia R., Agnus D., et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993, 94:109-110.
24. Colquhoun D.M., Jackson R., Walters M., et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans. Eur J Clin Invest 2005, 35:251-258.
25. De Pinieux G., Chariot P., Ammi-Said M., et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996, 42:333-337.
26. Elmberger P.G., Kalen A., Lund E., et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991, 32:935-940.
27. Folkers K., Langsjoen P., Willis R., et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990, 87:8931-8934.
28. Ghirlanda G., Oradei A., Manto A., et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993, 33:226-229.
29. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995, 57:62-66.
30. Laaksonen R., Jokelainen K., Laakso J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996, 77:851-854.
31. Lamperti C., Naini A.B., Lucchini V., et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005, 62:1709-1712.
32. Mabuchi H., Haba T., Tatami R., et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981. Atheroscler Suppl 2004, 5:51-55.
33. Mabuchi H., Higashikata T., Kawashiri M., et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005, 12:111-119.
34. Rundek T., Naini A., Sacco R., Coates K., DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004, 61:889-892.
35. Schaefer W.H., Lawrence J.W., Loughlin A.F., et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004, 194:10-23.
36. Stocker R., Pollicino C., Gay C.A., et al. Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study. Atherosclerosis 2006, 187:198-204.
37. Strey C.H., Young J.M., Molyneux S.L., et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005, 179:201-206.
38. Walravens P.A., Greene C., Frerman F.E. Lovastatin, isoprenes, and myopathy. Lancet 1989, 2:1097-1098.
39. Willis R.A., Folkers K., Tucker J.L., et al. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A 1990, 87:8928-8930.
40. Päivä H., Thelen K.M., Van Coster R., et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005, 78:60-68.
41. Thomas J.E., Lee N., Thompson P.D. Statins Provoking MELAS Syndrome. A case report. Eur Neurol 2007, 57:232-235.
42. Oh J., Ban M.R., Miskie B.A., et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.
43. Puccetti L., Ciani F., Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010, 211:28-29.
44. Wagner B.K., Kitami T., Gilbert T.J., et al. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 2008, 26:343-351.
45. Baker S.K., Vladutiu G.D., Peltier W.L., Isackson P.J., Tarnopolsky M.A. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci 2008, 35:94-97.
46. Kaufmann P., Torok M., Zahno A., et al. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006, 63:2415-2425.
47. Sirvent P., Mercier J., Vassort G., et al. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005, 329:1067-1075.
48. Sacher J., Weigl L., Werner M., et al. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005, 314:1032-1041.
49. Tsao C.Y., Mendell J.R. Combined partial deficiencies of carnitine palmitoyltransferase II and mitochondrial complex I presenting as increased serum creatine kinase level. J Child Neurol 2002, 17:304-306.
50. Baker S.K., Tarnopolsky M.A. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001, 24:258-272.
51. Baker S.K., Samjoo I.A. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008, 35:8-21.
52. Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J Clin Rheumatol 2001, 7:340-345.
53. Goldman J.A., Fishman A.B., Lee J.E., Johnson R.J. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989, 32:358-359.
54. Khattak F.H., Morris I.M., Branford W.A. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994, 33:199.
55. Noel B., Cerottini J.P., Panizzon R.G. Atorvastatin-induced dermatomyositis. Am J Med 2001, 110:670-671.
56. Schalke B.B., Schmidt B., Toyka K., Hartung H.P. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992, 327:649-650.
57. Vasconcelos O.M., Campbell W.W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004, 30:803-807.
58. Needham M., Fabian V., Knezevic W., et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007, 17:194-200.
59. Singh P., Kohr D., Kaps M., Blaes F. Skeletal muscle cell MHC I expression: implications for statin-induced myopathy. Muscle Nerve 2010, 41:179-184.
60. Grable-Esposito P., Katzberg H.D., Greenberg S.A., et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185-190.
61. Christopher-Stine L., Casciola-Rosen L.A., Hong G., et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
62. Mammen A.L., Chung T., Christopher-Stine L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63:713-721.
63. Laaksonen R., Katajamaa M., Paiva H., et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1:e97.
64. Bays H. Statin safety: an overview and assessment of the data--2005. Am J Cardiol 2006, 97:6C-26C.
65. Harper C.R., Jacobson T.A. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007, 18:401-408.
66. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
67. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA 2003, 289:1681-1690.
68. Wilke R.A., Lin D.W., Roden D.M., et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev 2007, 6:904-916.
69. Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
70. Chan J., Hui R.L., Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother 2005, 39:1611-1616.
71. Graham D.J., Staffa J.A., Andrade S.E., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590.
72. Bruckert E., Hayem G., Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
73. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539-540.
74. Silva M.A., Swanson A.C., Gandhi P.J., et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006, 28:26-35.
75. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother 2001, 35:908-917.
76. Evans M.A., Golomb B.A. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacother 2009, 29:800-811.
77. McGuinness B., Craig D., Bullock R., et al. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009, 2. CD003160.
78. Benito-Léon J., Louis E.D., Vega S., et al. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimer Dis 2010, 21:95-102.
79. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentrations and mortality. BMJ 1990, 301:309-314.
80. Davey Smith G., Song F., Sheldon T.A. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993, 306:1367-1373.
81. Morgan R., Palinkas L., Barrett-Connor E., et al. Plasma cholesterol and depressive symptoms in older men. Lancet 1993, 341:75-79.
82. While A., Keen L. The effects of statins on mood: a review of the literature. Eur J Cardiovasc Nurs 2010, [Epub ahead of print].
83. Tuccori M., Lapi F., Testi A., et al. Statin-associated psychiatric adverse events. Drug Saf 2008, 31:1115-1123.
84. Schaefer E.J. Letter to the editor. N Engl J Med 1988, 319:1222.
85. Black D.M., Lamkin G., Olivera E.H., et al. Sleep disturbance and HMG CoA reductase inhibitors. JAMA 1990, 264:1105.
86. Vgontzas A.N., Kales A., Bixler E.O., et al. Effects of lovastatin and pravastatin on sleep efficency and sleep stages. Clin Pharmacol Ther 1991, 50:730-737.
87. Ehrenberg B.L., Lamon-Fava S., Corbett K.E., et al. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholersterolemic subjects. Sleep 1999, 22:117-121.
88. Rzouq F.S., Volk M.L., Hatoum H.H., et al. Hepatotoxicity fears contribute to underutilization of station medications by primary care physicians. Am J Med Sci 2010, 340:89-93.
89. Calderon R.M., Cubeddu L.X., Golberg R.B., et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010, 85:349-356.
90. Bhardwaj S.S. Lipid lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007, 11:597-613. vii.
91. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
92. Pfeffer M.A., Keech A., Sacks F.M., et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002, 105:2341-2346.
93. Alla V., Abraham J., Siddiqui J., et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006, 40:757-761.
94. Gomez-Dominguez E., Gisbert J.P., Moreno-Monteagudo J.A., et al. A pilot study of atorvastatin treatment in dyslipemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
95. American Gastroenterological Association medical position statement. Non alcoholic fatty liver disease. Gastroenterology 2002, 123:1702-1704. American Gastroenterological Association.
96. Wiesinger H.A., Shah J., White A., et al. Liver biochemistry abnormalities in a quaternary care lipid clinic database. Ann Hepatol 2008, 7:63-66.
97. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006, 44:466-471.
98. Hyogo H., Tazuma S., Arihiro K., et al. Efficacy of atorvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia. Metab Clin Exp 2008, 57:1711-1718.
99. Argo C.K., Loria P., Caldwell S.H., et al. Statins in liver disease: a molehill, an iceberg or neither?. Hepatology 2008, 48:662-669.
100. Foster T., Budoff M.J., Saab S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106:71-77.
101. Tandra S., Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009, 11:272-278.
102. Aburajab M.A., Kaplan M.M. Statin use in patients with primary billiary cirrhosis (PBC): are they safe? [abstract]. Gastroenterology 2007, 132:A732.
103. Vuppalanchi R., Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe?. Clin Gastroenterol Hepatol 2006, 4:838-839.
104. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010, 105:978-980.
105. Brown W.V. Safety of statins. Curr Opin Lipidol 2008, 19:558-562.
106. Sidaway J.E., Davidson R.G., McTaggart F., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004, 15:2258-2265.
107. Agarwal R. Statin induced proteinuria: renal injury or renoprotection?. J Am Soc Nephrol 2004, 15:2502-2503.
108. Verhulst A., D'Haese P.C., De Broe M.E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249-2257.
109. Fellström B., Holdaas H., Jardine A.G., et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004, 66:1549-1555.
110. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010, 160:785-794. Sharp Collaborative Group.
111. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
112. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
113. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
114. de Zeeuw D. Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. Presented at: 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 25-28, 2010; Munich, Germany.
115. Kasiske B.L., Wanner C., O'Neill W.C., et al. An assessment of statin safety by nephrologists. Am J Cardiol 2006, 97:82C-85C.
116. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
117. Coleman C.I., Reinhart K., Kluger J., et al. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008, 24:1359-1362.
118. Rajpathak S.N., Kumbhani D.J., Crandall J., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
119. Baker W.L., Talati R., White C.M., et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
120. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
121. Campian J., Western A. Statins and joint pain. Br J Clin Phamacol 2008, 66:570-571.
122. Liebhaber M.I., Wright R.S., Gelberg H.J., Dyer Z., Kupperman J.L. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999, 115:886-889.
123. Chazerain P., Hayem G., Hamza S., Best C., Ziza J.M. Four cases of tendinopathy in patients on statin therapy. Jt Bone Spine 2001, 68:430-433.
124. Movahed M.R., Samsamsharaiat S.A. Reproducible tendinitis-like symptoms related to statin therapy. J Clin Rheumatol 2006, 12:320-321.
125. Pullatt R.C., Gadarla M.R., Karas R.H., Alsheikh-Ali A.A., Thompson P.D. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol 2007, 100:152-153.
126. Marie I., Delafenetre H., Massy N., et al. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum 2008, 59:367-372.
127. Turner N.A., O'Regan D.J., Ball S.G., Porter K.E. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005, 19:804-806.
128. Beri A., Dwamena F.C., Dwamena B.A. Association between statin therapy and tendon rupture. A case-control study. J Cardiovasc Pharmacol 2009, 53:401-404.
129. Beattie M., Lane N., Hung Y.Y., Nevitt M.C. Association of statin use and development and progression of hip osteoarthritis in elderly women. J Rheumatol 2005, 32:106-110.
130. Soubrier M., Roux C. Statins in rheumatology. Joint Bone Spine 2006, 73:159-168.
131. Roman M.J., Salmon J.E. Cardiovascular manifestations of rheumatologic diseases. Circulation 2007, 116:2346-2355.
132. Solomon D.H., Goodson N.J., Katz J.N., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006, 65:1608-1612.
133. Kitsas G.D., Gabriel S. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011, 70:8-14.
134. Arnaud C., Mach F. Potnetial anti-inflammatory and immunomodulator effects of statins in rheumatologic therapy. Arthritis Rheum 2006, 54:390-392.
135. Nurmohamed M.T., Dijkmans B.A. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009, 68:453-455.
136. McCarey D.W., McInnes E.B., Madhok R., et al. Trial of atorvastatin in rheumatoid arthritis (TARA): a double-blind randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
137. Lodi S., Evans S.J.W., Egger P., Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis?. Analysis of a large routinely collected claims database. Br J Clin Pharmacol 2010, 69:85-94.
138. Toms T.E., Panoulas V.F., Douglas K.M.J., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69:683-688.
139. Semb A.G., Holme I., Kvien T.K., Pedersen T.R. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011, 50:324-329.
140. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
141. Randall V.A. Androgens: the main regulator of human hair growth. Hair and Its Disorders: Biology, Pathology and Management 2000, 69-82. Martin Dunitz, London. F.M. Camacho, V.A. Randall, V.H. Price (Eds.).
142. Lipitor Product Monograph. Updated November 17 2010, Pfizer Canada Inc.
143. Crestor Product Monograph. Updated October 15 2010, Astra Zeneca Canada Inc.
144. Zocor Product Monograph. Updated October 12 2010, Merck Frosst Canada Ltd.
145. Lescol Product Monograph. Updated October 12 2010, Novartis Pharmaceuticals Canada Inc.
146. Pravachol Product Monograph. Updated October 12 2010, Bristol-Myers Squibb Canada Inc.
147. Mevacor Product Monograph. Updated October 12 2010, Merck Frosst Canada Ltd.
148. Segal A.S. Alopecia associated with atorvastatin. Am J Medicine 2002, 113:171.
149. Robb-Nicholson C. Recently, I heard on a TV show that anticholesterol drugs can cause hair loss. I've been taking Zocor for about 18 months now, and in the past 6 months I've noticed hair loss from the top and sides of my head. Is this common? Will my hair regrow once I stop taking the drug?. Harv Womens Health Watch 1998, 5:8.
150. Lee T.H. By the way, doctor My hair has been thinning out for the past decade or so, but since my doctor started me on Lipitor (atorvastatin) a few months ago for high cholesterol, I swear it's been falling out much faster. My doctor discounts the possibility, but I looked in the Physicians' desk reference (PDR) and alopecia is listed under "adverse reactions." What do you think?. Harv Health Lett 2000, 25:8.
151. Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009, 84:139-148.
152. Jones T.H. Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. Eur Urol Suppl 2007, 6:847-857.
153. Ferrer E., Moral M.A., Bozzo J. The role of statins in erectile dysfunction. Drugs Today (Barc) 2007, 43:55-59.
154. Solomon H., Wierzbicki A.S., Lumb P.J., et al. Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am J Hypertens 2006, 19:915-919.
155. Hermann H.C., Levine L.A., Macalusa J., et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil?. Hypothesis and pilot trial results. J Sex Med 2006, 3:303-308.
156. Azzarito C., Boiardi L., Zini M., et al. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients. Metabolism 1992, 41:148-153.
157. Dobs A.S., Schrott H., Davidson M.H., et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000, 49:1234-1238.
158. Travia D., Tosi F., Negri C., et al. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab 1995, 80:836-840.
159. Stanworth R.D., Kapoor D., Channer K.S., et al. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009, 32:541-546.
160. Rossato M., Guarneri G., Lavagnini T., et al. Simvastatin influences testicular steroidogenesis in human. Horm Metab Res 1993, 25:503-505.
161. Jay R.H., Sturley R.H., Stirling C., et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 1991, 32:417-422.
162. Hyyppä M.T., Kronholm E., Virtanen A., et al. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men?. A randomized double-blind trial. Psychoneuroendocrinology 2003, 28:181-194.
163. Corona G., Boddi V., Balercia G., et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010, 7:1547-1556.
164. Hall S.A., Page S.T., Travison T.G., et al. Do statins affect androgen levels in men?. Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007, 16:1587-1594.
165. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
166. Fernandez A.B., Karas R.H., Alsheikh-Ali A.A., Thompson P.D. Statins and interstitial lung disease: a systematic review of the literature and of Food and Drug Administration Adverse Event Reports. Chest 2008, 134:824-830.
167. Nichols G.A., Koro C.E. Does statin therapy initiation increase the risk for myopathy?. An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007, 29:1761-1770.
168. Holbrook A., Wright M., Sung M., Ribic C., Baker S. Statin-associated rhabdomyolysis: Is there a dose-response relationship?. Can J Cardiol 2011, 27:146-151.
169. Vladutiu G.D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655.
170. Fiegenbaum M., da Silveira F.R., Van der Sand C.R., et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005, 78:551-558.
171. Frudakis T.N., Thomas M.J., Ginjupalli S.N., et al. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007, 17:695-707.
172. Hermann M., Bogsrud M.P., Molden E., et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006, 79:532-539.
173. Mulder A.B., van Lijf H.J., Bon M.A., et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001, 70:546-551.
174. Ruano G., Thompson P.D., Windemuth A., et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007, 36:329-335.
175. Vaklavas C., Chatzizisis Y.S., Ziakas A., et al. Molecular basis of statin-associated myopathy. Atherosclerosis 2009, 202:18-28.
176. Evans M., Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug Saf 2002, 25:649-663.
177. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80:565-581.
178. Rosenson R. Current overview of statin-induced myopathy. Am J Med 2004, 116:408-416.
179. McClure D.L., Valuck R.J., Glanz M., Murphy J.R., Hokanson J.E. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol 2007, 60:812-818.
180. Stefanick M.L., Mackey S., Sheehan M., et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998, 339:12-20.
181. Schaefer E.J., Lamon-Fava S., Ausman L.M., et al. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. Am J Clin Nutr 1997, 65:823-830.
182. Mensink R.P., Katan M.B. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. N Engl J Med 1989, 321:436-441.
183. Kris-Etherton P.M., Pearson T.A., Wan Y., et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr 1999, 70:1009-1015.
184. Abumweis S.S., Barake R., Jones P.J. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008, 52.
185. Jenkins D.J., Leeds A.R., Gassull M.A., et al. Decrease in postprandial insulin and glucose concentrations by guar and pectin. Ann Intern Med 1977, 86:20-23.
186. Bourdon I., Yokoyama W., Davis P., et al. Postprandial lipid, glucose, insulin and cholecystokinin responses in men fed barley pasta enriched with beta-glucan. Am J Clin Nutr 1999, 69:55-63.
187. Kendall C.W., Jenkins D.J. A dietary portfolio: maximal reduction of low-density lipoprotein cholesterol with diet. Curr Atheroscler Rep 2004, 6:492-498.
188. Jenkins D.J., Kendall C.W., Marchie A., et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003, 290:502-510.
189. Dattilo A.M., Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
190. Halbert S.C., French B., Gordon R.Y., et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198-204.
191. Becker D.J., Gordon R.Y., Halbert S.C., et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830-839.
192. Gordon R.Y., Becker D.J. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011, 13:73-80.
193. Stein E.A., Ballantyne C.M., Windler E., et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008, 101:490-496.
194. Degreef L.E., Opdam F.L., Teepe-Twiss I.M., et al. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. Eur J Intern Med 2010, 21:293-296.
195. Glueck C.J., Aregawi D., Agloria M., et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther 2006, 28:933-942.
196. Backes J.M., Venero C.V., Gibson C.A., et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341-346.
197. Joy T., Hegele R.A. Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients [comment on Can J Cardiol 2009;25:e28-31]. Can J Cardiol 2009, 25:453.
198. Backes J.M., Moriarty P.M., Ruisinger J.F., et al. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007, 100:554-555.
199. Jia L., Betters J.L., Yu L. Niemann-Pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol 2011, 73:239-259.
200. Hegele R.A., Guy J., Ban M.R., et al. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis 2005, 4:16.
201. Athyros V.G., Tziomalos K., Kakafika A.I., et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008, 101:483-485.
202. Stein E.A., Ballantyne C.M., Windler E., et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008, 101:490-496.
203. Zema M.J. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005, 12:306-310.
204. Brooks E.L., Kuvin J.T., Karas R.H. Niacin's role in the statin era. Expert Opin Pharmacother 2010, 11:2291-2300.
205. Bays H.E., Shah A., Lin J., et al. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol 2010, 4:515-521.
206. Berge K.G., Canner P.L. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991, 40(suppl 1):S49-S51.
207. Goldenberg I., Benderly M., Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag 2008, 4:131-141.
208. Tenenbaum H., Behar S., Boyko V., et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007, 194:265-271.
209. Tenenbaum A., Motro M., Fisman E.Z., et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038.
210. Asztalos B.F., Collins D., Cupples L.A., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005, 25:2185-2191.
211. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
212. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27. The BIP Study Group.
213. Tenenbaum A., Motro M., Fisman E.Z., et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
214. Goldenberg I., Benderly M., Goldbourt U., et al. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol 2008, 51:459-465.
215. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
216. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. ACCORD Study Group.
217. Bays H.E., Goldberg R.B. The 'forgotten' bile acid sequestrants: is now a good time to remember?. Am J Ther 2007, 14:567-580.
218. Jacobson T.A., Armani A., McKenney J.M., Guyton J.R. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007, 99:47C-55C.
219. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255. HEART-UK LDL Apheresis Working Group.
220. Thompson G.R., Barbir M., Davies D., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
221. Richter W.O., Donner M.G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999, 3:203-208.
222. Gordon B.R. Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia. Curr Atheroscler Rep 2000, 2:308-313.
223. Matsuzaki M., Hiramori K., Imaizumi T., et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART). J Am Coll Cardiol 2002, 40:220-227.
224. Coker M., Ucar S.K., Simsek D.G., et al. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Ther Apher Dial 2009, 13:121-128.
225. Akdim F., Visser M.E., Tribble D.L., et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010, 105:1413-1419.
226. Abifadel M., Pakradouni J., Collin M., et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat 2010, 20:1547-1571.
227. Visser M.E., Kastelein J.J., Stroes E.S. Apolipoprotein B synthesis inhibition: results from clinical trials. Curr Opin Lipidol 2010, 21:319-323.
228. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
229. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009, 106:9820-9825.
230. Cuchel M., Bloedon L.T., Szapary P.O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356:148-156.
231. Caso G., Kelly P., McNurlan M.A., et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
232. Young J.M., Florkowski C.M., Molyneux S.L., et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007, 100:1400-1403.
233. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
234. Ahmed W., Khan N., Glueck C.J., et al. Low serum 25 (OH) vitamin D levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009, 153:11-16.
235. Gupta A., Thompson P.D. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011, 215:23-29.
236. Rosanoff A., Seelig M.S. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. J Am Coll Nutr 2004, 5:501S-505S.
237. El-Tawil S., Al Musa T., Valli H., et al. Quinine for muscle cramps. Cochrane Database Syst Rev 2010, 12. CD005044.
238. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008, 14:6774-6785.
239. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) July 2009, US Food and Drug Administration, Accessed July 22, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.